ASX ANNOUNCEMENT AGM CHAIR’S ADDRESS & MANAGING DIRECTOR PRESENTATION Perth, Australia; 19 November 2026 - Argenica Therapeutics Limited (ASX: AGN) (“Argenica” or the “Company”), is pleased to provide below copies of the Chair’s Address and Managing Director Presentation given at its...
AGM Chair Address & Presentation
Filed with ASX · · 2 pages · English
Summary by 6ix AI
This filing is an announcement regarding the Chair's Address and Managing Director Presentation at Argenica Therapeutics Ltd's Annual General Meeting. The trial successfully met its primary objective of testing safety and showed potential efficacy in more severe stroke patients, indicating significant milestones in neurology drug development.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Argenica Therapeutics Ltd on 6ix
Earlier from Argenica Therapeutics
- FDA Feedback Received, Requests Additional Rat Study
- Becoming a substantial holder
- Quarterly Activities/Appendix 4C Cash Flow Report
- New Mechanism Findings Offer Insights Into Phase 2 Signal
- Notice of Annual General Meeting/Proxy Form
Later from Argenica Therapeutics
All Argenica Therapeutics news releasesFollow Argenica Therapeutics into a list and get an email when it puts out news.
Follow Argenica Therapeutics